Summary of Bristol-Myers Squibb Company (NYSE:BMY) FY Conference Call Company Overview - **Company**: Bristol-Myers Squibb Company (BMY) - **Event**: TD Cowen's 46th Annual Healthcare Conference - **Date**: March 02, 2026 Key Points Industry and Market Dynamics - **2025 Performance**: Strong performance with good momentum into 2026, particularly from growth portfolio products like REVLIMID, Breyanzi, and CAMZYOS [3][4] - **Headwinds**: Full generics for REVLIMID and POMALYST are now in the market, impacting legacy portfolio revenue, but significant growth is expected from ELIQUIS [3][4] - **Operating Expenses**: Disciplined management of operating expenses, with a normalization expected in 2026 after higher expenses in the second half of 2025 due to partnerships and acquisitions [4][5] Product Performance - **CAMZYOS**: Annualized over $1 billion in sales, with consistent increases in new patients and prescribers, indicating strong market adoption despite competition [6][7] - **Opdivo Qvantig**: Positive performance with expectations to achieve a 30%-40% conversion rate by 2028, improving practice efficiency and patient experience [8][9] - **Cobenfy**: Good progress in its first year, with a focus on increasing prescriber adoption and upcoming data from a phase 4 switching study expected to enhance market penetration [10][11] Upcoming Trials and Data Readouts - **Alzheimer's Disease Psychosis Trials**: Three studies (ADEPT 1, 2, and 4) are expected to read out by the end of 2026, with confidence in the product's efficacy based on previous studies [16][17] - **Milvexin**: Anticipated data readouts in SSP and AFib by the end of 2026, with potential to become a new standard of care in atrial fibrillation due to a better bleeding profile compared to ELIQUIS [27][28] Future Growth Potential - **Admilprant**: Positioned for significant market potential in IPF and PPF, with expectations that the market could grow from $4 billion to between $8 billion and $10 billion due to improved diagnosis and treatment rates [36][38] - **Pipeline Assets**: Multiple assets expected to read out by the end of 2026, including Cobentfy, Milvexin, Iberidone, and Ibertamide, all showing strong commercial potential [33][35] Strategic Focus - **Long-term Growth Strategy**: The company aims to be the fastest-growing in the industry by the end of the decade, with a focus on sustainable growth through a diverse pipeline of products [51][52] - **Intellectual Property Defense**: Commitment to vigorously defend IP for key products like Opdivo, with a conservative planning date for loss of exclusivity set for December 2028 [43][44] Conclusion - **Overall Outlook**: Bristol-Myers Squibb is positioned for strong growth with a robust pipeline and strategic focus on long-term sustainability, aiming to leverage upcoming data readouts and market opportunities to enhance its competitive position in the pharmaceutical industry [52][53]

Financial Data and Key Metrics Changes - The company's net revenues for Q2 FY2026 were $861.4 million, representing a year-over-year increase of 39.1% in U.S. dollar terms and 38.1% in RMB terms [9][15][18] - Non-GAAP income from operations was $107.8 million, compared to $64.5 million in the same period last year [10][17] - Net income attributable to TAL was $124.1 million, up from $57.4 million year-over-year [18] Business Line Data and Key Metrics Changes - PAYU Small Class Enrichment Programs experienced growth driven by higher enrollments and expansion of offline learning centers [11][28] - The learning device business saw revenue growth both year-over-year and sequentially, with sales volumes increasing due to new product launches [14][35] - The average weekly active rate among learning device users was approximately 80%, with average data usage time per active device exceeding one hour [15] Market Data and Key Metrics Changes - The offline small class enrichment learning market is fragmented, making it challenging to assess total market size and demand [26] - The blended average selling price (ASP) for learning devices declined below RMB 4,000 due to changes in product mix [34] Company Strategy and Development Direction - The company is focused on long-term sustainable growth, investing in technology and content to enhance user engagement and learning outcomes [4][21] - A technology-driven approach is being adopted to improve online enrichment learning programs, integrating smart interactive features [12][35] - The company aims to strengthen its go-to-market capabilities in the learning device sector, which is still in its early stages [22] Management's Comments on Operating Environment and Future Outlook - Management acknowledged potential fluctuations in business performance due to seasonal factors but remains committed to long-term growth [21][23] - The company is prioritizing resource allocation to critical areas aligned with long-term strategic goals, focusing on sustainable growth rather than short-term financial results [22][23] Other Important Information - The company has authorized a new share repurchase program of approximately $600 million, with $134.7 million spent on repurchasing shares so far [19][50] - As of August 31, 2025, the company held approximately $3.5 billion in cash and cash equivalents, short-term investments, and restricted cash [50] Q&A Session Summary Question: Updates on PAYU Small Class Enrichment Programs - Management noted steady growth in PAYU Small Class Enrichment Programs, with revenue growth in line with learning center expansion and stable pricing for summer courses [26][28] Question: Performance of Learning Device Business - The learning device business saw increased sales volumes, but the blended ASP declined due to product mix changes; the company remains focused on long-term competitiveness [34][35] Question: Breakdown of Top Line and Bottom Line Performance - Management indicated that PAYU Small Class revenue growth is expected to taper off, while learning devices are still in early stages with fluctuating performance [43][45] Question: Share Repurchase Plan Outlook - The company will continue to execute the share repurchase program in line with market conditions, maintaining a long-term perspective on capital allocation [50]